{"id":825882,"date":"2025-03-14T08:38:14","date_gmt":"2025-03-14T12:38:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/"},"modified":"2025-03-14T08:38:14","modified_gmt":"2025-03-14T12:38:14","slug":"polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/","title":{"rendered":"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Raanana, Israel, March  14, 2025  (GLOBE NEWSWIRE) &#8212;  Polyrizon Ltd. (Nasdaq: PLRZ) (the \u201cCompany\u201d or \u201cPolyrizon\u201d), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (\u201cthe psychedelic company\u201d), to develop a novel intranasal formulation for psychedelic-based treatment applications.<\/p>\n<p>This agreement aims to leverage Polyrizon\u2019s proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further clinical development and commercialization.<\/p>\n<p>\u201cOur proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a prolonged drugs residence time and more efficient alternative to traditional administration methods,\u201d said Tomer Izraeli CEO of Polyrizon.<\/p>\n<p>According to the non-binding LOI, Polyrizon will lead the formulation\u2019s development, utilizing its mucoadhesive drug delivery technology to enhance the absorption and effectiveness of the psychedelic company\u2019s treatment. The psychedelic company will fund the research and development process, including feasibility studies, ensuring the project progresses efficiently toward clinical validation. Pursuing a successful outcome the two companies intend to negotiate a definitive agreement following proof of concept, outlining intellectual property ownership, commercialization rights, and financial terms. Polyrizon will receive royalty payments for any future commercialization of the product by the psychedelic company.<\/p>\n<p>\n        <strong>About Polyrizon<\/strong>\n      <\/p>\n<p>Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon\u2019s proprietary Capture and Contain\u00a0<sup>TM<\/sup>, or C&amp;C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a \u201cbiological mask\u201d with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&amp;C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target \u2122, or T&amp;T. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s0k2MdQiBq7DqDZbwkqvkdly8oLCySMexWheG6alIHMvlMEJAsG7BD4QLW7D03fVQMtcoIdcV_a7FmTQmvKDgqDnEC7rMOkGeUbzKqGzwN5lI5RaFpyUhXd_GsMkWZHZ\" rel=\"nofollow\" target=\"_blank\">https:\/\/polyrizon-biotech.com<\/a>.<\/p>\n<p><strong>Forward Looking Statements<\/strong><\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the execution of definitive agreements with the psychedelic company, its belief that intranasal delivery has the potential to improve patient outcomes by providing a prolonged drugs residence time\u00a0and more efficient alternative to traditional administration methods and how this collaboration, if successful, has the potential to pave the way for further clinical development and commercialization. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC.. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.<\/p>\n<p>Contacts:<\/p>\n<p>Michal Efraty<br \/>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N9cSfSEh5lshRjtWXd92bz4aFvGvEA31r0CixXMyD3qC0GYgmOIvgx1Sny-mvm7hkXtsu_zqqrAGvxbb-E4Yc4rpbBb1Sp9neEOAIZad6--QGjamWvXeny9MkdCPjGLe\" rel=\"nofollow\" target=\"_blank\">IR@polyrizon-biotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWZkYTE2YjItOGRiZi00MzJhLWJjNjEtNTgwYjVlOGM3MjM1LTUwMDEyOTIyMy0yMDI1LTAzLTE0LWVu\/tiny\/Polyrizon-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) &#8212; Polyrizon Ltd. (Nasdaq: PLRZ) (the \u201cCompany\u201d or \u201cPolyrizon\u201d), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (\u201cthe psychedelic company\u201d), to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyrizon\u2019s proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-825882","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) &#8212; Polyrizon Ltd. (Nasdaq: PLRZ) (the \u201cCompany\u201d or \u201cPolyrizon\u201d), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (\u201cthe psychedelic company\u201d), to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyrizon\u2019s proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further &hellip; Continue reading &quot;Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-14T12:38:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments\",\"datePublished\":\"2025-03-14T12:38:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/\"},\"wordCount\":841,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/\",\"name\":\"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==\",\"datePublished\":\"2025-03-14T12:38:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/","og_locale":"en_US","og_type":"article","og_title":"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - Market Newsdesk","og_description":"Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) &#8212; Polyrizon Ltd. (Nasdaq: PLRZ) (the \u201cCompany\u201d or \u201cPolyrizon\u201d), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (\u201cthe psychedelic company\u201d), to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyrizon\u2019s proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further &hellip; Continue reading \"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-14T12:38:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments","datePublished":"2025-03-14T12:38:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/"},"wordCount":841,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/","name":"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==","datePublished":"2025-03-14T12:38:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NDY0NyM2ODA2NjA4IzUwMDEyOTIyMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Polyrizon Signs Non\u2013 Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/825882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=825882"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/825882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=825882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=825882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=825882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}